{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T13:00:10Z","timestamp":1780750810416,"version":"3.54.1"},"reference-count":25,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Novartis Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)\/computed tomography (CT) imaging has demonstrated clinical value for individuals with prostate cancer (PC). In this phase 2 study, we measured the pharmacokinetics and dosimetry of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 in Chinese participants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Adult Chinese participants with progressive metastatic castration-resistant PC (mCRPC) received a single intravenous [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 dose of approximately 150 MBq. Blood samples were collected at 5, 15, 30, 45, 85, 175, and 245 min post injection for pharmacokinetics assessments. Whole-body PET scans and low\/ultra-low-dose CT scans were acquired at 30, 60, 120, and 255 min post injection for dosimetry assessments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Pharmacokinetics and dosimetry assessments were completed in seven participants who received a [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 dose (range: 108.3\u2013236.7 MBq). In the blood, the geometric mean effective terminal half-life was 1.34 h (geometric coefficient of variation [geo-CV], 182%); geometric mean clearance was 9.80 L\/h (geo-CV, 106%). The highest absorbed doses were seen in the kidneys, urinary bladder walls, and lacrimal glands. In the study population, the geometric mean (geo-CV) effective dose of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 was 4.2 mSv (32.9%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      The pharmacokinetic and dosimetry profiles of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11, assessed using a validated method in participants with progressive mCRPC, make it very suitable with proves its suitability.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10849785251415122","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T12:07:59Z","timestamp":1771070879000},"page":"430-438","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics and Dosimetry of [\n                    <sup>68<\/sup>\n                    Ga]Ga-PSMA-11 in Chinese Participants with Progressive Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Study"],"prefix":"10.1177","volume":"41","author":[{"given":"Wei","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongcheng","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Zhongshan Hospital, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Urology, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking University Cancer Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University Cancer Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nanjing First Hospital, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Xijing Hospital, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danfeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Jiang","sequence":"additional","affiliation":[{"name":"Novartis Biomedical Research, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifu","family":"Li","sequence":"additional","affiliation":[{"name":"Novartis Development, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Li","sequence":"additional","affiliation":[{"name":"Novartis Development, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runqin","family":"Li","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-083X","authenticated-orcid":false,"given":"Li","family":"Huo","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Ji","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.853623"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2015.42"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115966"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-018-0239-2"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.154153"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3188-1"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.173492"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.021"},{"key":"e_1_3_5_11_2","unstructured":"US Food and Drug Administration. Locametz (kit for the preparation of gallium Ga 68 gozetotide) [package insert]. Novartis AG. 2023. Available from: https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/locametz.pdf [Last accessed: 22October]."},{"key":"e_1_3_5_12_2","unstructured":"European Medicines Agency. Locametz (gozetotide) [product information]. Novartis Europharm Limited. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/locametz-epar-product-information_en.pdf [Last accessed: 14November]."},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262305"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123020"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-014-9691-7"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06640-x"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-025-02079-8"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-016-3419-0"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-016-3424-3"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/rpd\/ncy111"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2016.11.002"},{"key":"e_1_3_5_22_2","unstructured":"International Commission on Radiological Protection. Basic Anatomical and Physiological Data for Use in Radiological Protection Reference Values. 2002. Available from: http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/ANIB_32_3-4 [Last accessed: October24]."},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1072-6"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.icrp.2006.03.004"},{"key":"e_1_3_5_25_2","unstructured":"International Commission on Radiological Protection. The 2007 recommendations of the International Commission on Radiological Protection. 2007. Available from: https:\/\/www.icrp.org\/docs\/icrp_publication_103-annals_of_the_icrp_37(2-4)-free_extract.pdf [Last accessed: 18December]."},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265448"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10849785251415122","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10849785251415122","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10849785251415122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:20:41Z","timestamp":1780748441000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10849785251415122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,6,1]]}},"alternative-id":["10.1177\/10849785251415122"],"URL":"https:\/\/doi.org\/10.1177\/10849785251415122","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]}}}